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The authors regret that one affiliation address is mistaken in the
published paper. Matthew Bridgland-Taylor's affiliation was incorrectly
listed as Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca,
Cambridge, United Kingdom. The correct affiliation is Clinical
Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca,
Cambridge, United Kingdom.
The authors would like to apologise for any inconvenience caused.
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